Growth and change in the prescribing of anti-depressants in New Zealand: 1993-1997

New Zealand Medical Journal

Volumn 114, Issue 1125, 2001, Pages 25-27

  Roberts, Evan ^a,b   Norris, Pauline ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG ADMINISTRATION; DRUG COST; DRUG UTILIZATION; ECONOMICS; HUMAN; NEW ZEALAND; PRESCRIPTION; PUBLIC HEALTH; RETROSPECTIVE STUDY; STATISTICS;

ANTIDEPRESSIVE AGENTS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG UTILIZATION; HUMANS; NATIONAL HEALTH PROGRAMS; NEW ZEALAND; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 0035830932     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Kaplan HI, Sadock BJ, editors. Synopsis of psychiatry. Baltimore: Williams and Wilkins; 1998.
2. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors for major depression. Part II. The cost effectiveness of SSRIs in treatment of depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997.
3. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors for major depression. Part I. Evaluation of the clinical literature. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997.
4. National Health Committee. Guidelines for the treatment and management of depression by primary healthcare professionals. Wellington: National Health Committee; 1996.
5. Stewart A. Choosing an anti-depressant: effectiveness based pharmacoeconomics. J Affect Dis 1998; 48: 125-33.
6. Donoghue J, Tylee A, Wildgust II. Cross sectional database analysis of anti-depressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996; 313: 861-2.
7. Freemantle N, Mason JM, Watt I. Evidence into practice: prescribing selective serotonin reuptake inhibitors. Int J Technol Assess Health Care 1998; 14: 387-91.
8. Nordic Statistics on Medicines 1993-1995. Uppsala: Nordic Council on Medicines; 1996.
9. Pathiyal A, Hylan T, Jones J et al. Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in The Netherlands a multivariate analysis. Clin Ther 1997; 19: 798-810.
10. Katelznick DJ, Kobak KA, Jefferson JW et al. Prescribing patterns of anti-depressant medications for depression in a HMO. Formularly 1996; 31: 374-88.
11. Rosholm J-U, Hallas J, Gram LF. Outpatient utilisation of anti-depressants: a prescription database analysis. J Affect Dis 1993; 27: 21-8.
12. Olfson M, Marcus SC, Pincus HA et al. Anti-depressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998; 55: 310-6.
13. Pincus HA, Taniclian TL, Marcus SC et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 1998; 279: 526-31.
14. SAS Institute. SAS Procedures Guide, Version 6. Third ed. Cary: SAS Institute; 1990.
15. Reserve Bank of New Zealand. Monetary policy statement. Wellington: 1998.
16. Brown MC. Developing an implicit price deflator for New Zealand's health sector. New Zealand Economic Papers 1997, 31: 15-34.
17. Ellis J, Devlin A, Galapitage C. Health expenditure trends in New Zealand 1980-1997. Wellington: Ministry of Health; 1998.
18. Rotherham F. Prozac windfall buoys PHARMAC. The Independent 1998; 16: September 7.